Britain’s Medicinal Rivers: The Drugs We Excrete and the Water We Drink

Blurs.co.uk
17 Min Read
Summarize with AI

Every day, millions of people in Britain take medicines that make modern healthcare possible. Painkillers ease suffering, antibiotics fight infections, antidepressants help manage serious illness and medicines for blood pressure, epilepsy and heart disease prevent countless deaths. But after a dose has done its work, some of its chemical ingredients leave the body and enter the sewage system. Wastewater treatment removes many contaminants, but it was not originally designed to eliminate every pharmaceutical molecule. As a result, residues of medicines have been measured in treated sewage and in rivers across the country.

This is not an argument against medication, nor evidence that drinking water is routinely unsafe. It is a less visible environmental consequence of modern medicine: a continuous flow of biologically active chemicals into aquatic ecosystems, where mixtures of substances may expose wildlife over long periods. The science is nuanced, the concentrations are often tiny, and the risks differ enormously between compounds. But the evidence is sufficient to make pharmaceutical pollution a serious subject for investigation.

The journey from medicine cabinet to river

After a medicine is swallowed, the body may absorb it, transform it into other chemicals known as metabolites, store or distribute it in tissues, and eventually eliminate the original compound and its breakdown products. The proportions vary according to the drug, dose, individual physiology and route of administration.

Some medicines are metabolised extensively. Others leave the body with a substantial proportion of the original active ingredient intact. A frequently cited UK review published in 2005 compiled examples from the pharmacological literature: it reported that around 90% of an atenolol dose could be excreted unchanged, compared with approximately 60% for amoxicillin and 50% for cetirizine. The same table gave lower figures for ibuprofen (10%) and paracetamol (4%). These are historical, drug-specific estimates drawn from the references available to that review, not universal values for every patient or formulation.

“Unchanged” is an important distinction. It means the molecule is excreted in its original chemical form, rather than first being converted by the body into a different metabolite. It does not, by itself, tell us how much of a dose reaches a river, how long it remains there, or whether the concentration is harmful to wildlife.

Which medicines can pass through largely unchanged?

The 2005 review, Household Disposal of Pharmaceuticals as a Pathway for Aquatic Contamination in the United Kingdom, included the following illustrative estimates of urinary excretion of unchanged active ingredient:

MedicineCommon useReported unchanged excretion
AtenololBeta-blocker used for cardiovascular conditionsAbout 90%
AmoxicillinAntibioticAbout 60%
CetirizineAntihistamineAbout 50%
ErythromycinAntibioticAbout 25%
SulfamethoxazoleAntibioticAbout 15%
IbuprofenAnti-inflammatory painkillerAbout 10%
ParacetamolPainkillerAbout 4%
CarbamazepineMedicine used for epilepsy and some other conditionsAbout 3%

These figures need careful interpretation. They come from a review published more than two decades ago and should be treated as indicative examples, not a current national survey. Different studies may report different values depending on the dose, population, sampling period and whether they measure urine, faeces or total elimination. A low percentage excreted unchanged also does not mean a medicine is environmentally irrelevant: metabolites can persist, be transformed back into parent compounds, or have biological effects of their own.

Why sewage treatment does not remove everything

Most wastewater treatment works rely on combinations of screening, settlement and biological processes. Microorganisms break down organic matter; solids are separated; and treated effluent is discharged under regulated conditions. These processes are essential for public health and river protection, but conventional treatment was not designed as a universal chemical filter.

Some pharmaceutical compounds are readily biodegraded or removed. Others resist breakdown, remain dissolved in water, or attach to sludge. Removal also depends on the design and operation of the treatment works, temperature, retention time, chemical properties and the presence of additional treatment stages. “Removal” can mean degradation, transfer into sludge, or a reduction in measured concentration; those outcomes are not interchangeable.

A study published in 2009 examined pharmaceutical residues at three wastewater treatment works in England and in the River Ouse downstream of one discharge. Five compounds — propranolol, sulfamethoxazole, carbamazepine, indomethacin and diclofenac — were detected in all wastewater and river-water samples. Removal varied between compounds and works, from 43% to 92%. The researchers found that the discharge from one works increased concentrations in the receiving river downstream of the outfall.

Research in the Rivers Ouse and Foss around York later demonstrated just how different the fate of individual medicines can be. In the treatment plants studied, removal ranged from effectively no elimination for carbamazepine to more than 99% for paracetamol. This is a useful corrective to the idea that all medicines simply pass through sewage works: some are removed very effectively, while others are much harder to deal with.

The river becomes the receiving environment

When treated wastewater enters a river, pharmaceutical residues are diluted by the receiving water. Dilution can reduce concentrations, but it does not necessarily eliminate the compounds. The resulting exposure depends on the volume and timing of the discharge, river flow, rainfall, temperature, sunlight, sediment and how quickly a substance breaks down.

In periods of low flow, treated effluent can make up a larger proportion of the water in some stretches of river. This can increase the relative importance of wastewater discharges, although actual concentrations must be measured at each location. A river is also not exposed to one chemical at a time. It may receive a changing mixture of prescription medicines, over-the-counter drugs, personal-care chemicals, agricultural pollutants and substances from industry.

Researchers therefore examine not only individual compounds but also the possibility of combined exposure. Chemicals present at low concentrations may act on different biological systems, and the effects of a mixture are not always predictable by looking at each ingredient in isolation. That does not mean every mixture is harmful; it means single-substance testing cannot answer every ecological question.

What can pharmaceutical residues do to wildlife?

Medicines are designed to interact with biological processes. A drug that changes heart rate, hormone signalling, brain chemistry or bacterial growth in humans may also interact with related systems in other organisms. Fish, invertebrates and algae are not small humans, however, and effects depend on species, exposure route, concentration and duration.

One of the clearest examples of pharmaceutical-related biological effects in British rivers concerns endocrine-active substances. The Environment Agency’s assessment of wild roach in English rivers reported that oestrogenic contaminants remained at levels capable of producing biological responses. Male fish were found with intersex characteristics associated with exposure to wastewater effluent containing natural and synthetic oestrogens. The report noted that effects persisted at many previously studied locations, although there were indications that concentrations may have fallen at some sites.

That finding should not be confused with proof that ordinary medicines alone caused the observed effects. The substances included natural and synthetic hormones and other contaminants with oestrogenic activity. It does demonstrate that chemicals entering rivers through wastewater can produce measurable biological changes in wildlife.

Other research has investigated antidepressants, beta-blockers, antibiotics and anti-inflammatory drugs in aquatic organisms. Depending on the compound and exposure conditions, studies have reported changes in behaviour, reproduction, growth or other physiological processes. Laboratory findings are important warning signals, but they do not automatically establish that the same effect is occurring in wild populations at typical river concentrations. Field studies, realistic exposure tests and long-term monitoring are needed to establish ecological significance.

Antibiotics and the problem of resistance

Antibiotics raise a particular concern because environmental exposure may influence the selection and spread of antimicrobial resistance. Wastewater can carry antibiotic residues, resistant bacteria and genes associated with resistance. Treatment processes reduce many microbial hazards, but they do not guarantee that every residue, bacterium or resistance gene is removed.

The relationship is complex. The presence of an antibiotic in a river does not prove that resistance will develop there, and the concentrations required to select for resistant organisms vary. Nevertheless, researchers are investigating wastewater systems as places where antibiotic residues, bacteria and resistance genes can meet. This matters because antimicrobial resistance is not confined to hospitals or farms; it is an environmental and public-health issue with multiple routes of transmission.

Unused medicines are another source

Not all pharmaceutical pollution comes from medicines excreted after use. Some unused or unwanted medicines are disposed of incorrectly by being flushed down toilets or poured into sinks. A study of five wastewater treatment plants in south-west England monitored 31 pharmaceuticals and identified episodes consistent with direct disposal of several medicines, including carbamazepine, propranolol, sildenafil, diltiazem, capecitabine and sertraline.

In one recorded episode, the researchers estimated that a large quantity of carbamazepine tablets had entered the sewer system. Their analysis showed that direct disposal could alter the pharmaceutical load arriving at a treatment works and change apparent removal performance. The practical message is straightforward: unwanted medicines should be returned to a pharmacy for safe disposal, not flushed or poured down the drain. Local pharmacy arrangements should be checked where necessary.

Could these substances reach drinking water?

The possibility deserves attention, but it needs to be described accurately. Rivers are sources of raw water for some drinking-water supplies, and water companies use treatment processes designed to make that water safe. Conventional drinking-water treatment can remove many contaminants, while advanced processes such as activated carbon and ozonation can provide additional removal for certain micropollutants.

Detection in a river does not mean the same concentration reaches a tap. Nor does detection at very low levels establish a health risk. Risk assessment considers the concentration, toxicity, duration of exposure and the sensitivity of the people or organisms exposed. For many pharmaceuticals, environmental concentrations are far below therapeutic doses, but long-term exposure to mixtures and the protection of aquatic ecosystems remain active research questions.

Monitoring by drinking-water researchers has examined selected pharmaceuticals and their metabolites in source water and through treatment. The Drinking Water Inspectorate has also published research on targeted monitoring for human pharmaceuticals. The evidence supports continued surveillance and treatment research, not a blanket claim that Britain’s tap water is contaminated with dangerous doses of medicines.

Can the problem be solved?

There is no single solution. Better treatment can help, but installing advanced processes everywhere would involve substantial energy, infrastructure and financial costs. Technologies such as activated carbon, ozonation and membrane filtration can remove a wider range of micropollutants, but performance varies by compound and each approach has operational considerations. Ozonation can also create transformation products that need to be understood and managed.

Prevention matters too. Pharmaceutical manufacturers, healthcare providers, regulators and water companies can contribute through better assessment of environmental persistence, improved prescribing and disposal guidance, targeted monitoring and treatment upgrades where the evidence shows they are needed. Drug design can also consider environmental fate alongside therapeutic effectiveness, without compromising patient care.

Monitoring needs to look beyond a handful of familiar substances. Researchers need to understand the combined presence of parent drugs, metabolites and transformation products, as well as seasonal changes and the consequences of low river flows. Publicly accessible data would help communities understand what is being measured, where, how often and against which environmental benchmarks.

A modern medical footprint

Pharmaceuticals are among the most important tools in modern medicine. Their environmental presence is not a reason to avoid prescribed treatment or to stop taking medication. The challenge is to recognise that medicines have a life beyond the patient: after they have served their purpose, their chemical components may continue through wastewater systems and into the natural environment.

The evidence from English wastewater works and rivers shows that residues of some medicines survive treatment and can be detected downstream. Other compounds, including paracetamol in the York study, were removed very efficiently. The ecological consequences vary, and the strongest evidence of biological effects in British fish includes endocrine disruption associated with wastewater contaminants more broadly, rather than a simple story of prescription drugs alone.

The important question is no longer whether pharmaceuticals can enter Britain’s rivers — research has demonstrated that they can. The questions now are which substances matter most, where exposure is greatest, what happens when chemicals combine, how treatment can be improved, and whether monitoring is keeping pace with the medicines society uses.

Related investigation: Read our follow-up, Which Pharmaceuticals Are Found in Britain’s Rivers — and How Do Levels Change with the Seasons?, examining the compounds most frequently detected in UK waterways and how river flow, rainfall and seasonal conditions affect their concentrations.

Further investigation

  • Which pharmaceutical compounds are most frequently detected in rivers across the UK, and how do concentrations change between seasons?
  • How much do low-flow conditions increase the proportion of treated wastewater in individual river catchments?
  • Which wastewater treatment works have advanced treatment stages capable of removing micropollutants, and where are the largest gaps?
  • How are pharmaceutical mixtures and metabolites included in current ecological risk assessments?
  • How consistently are antibiotic residues and antimicrobial-resistance markers monitored in receiving waters?
  • What information is publicly available from water companies and regulators about pharmaceutical monitoring and treatment performance?

Sources and references

Blurs note: The percentages in the excretion table are historical literature estimates and are included to illustrate differences between medicines. They should not be interpreted as current population averages or as the proportion that necessarily reaches rivers.

Share This Article
Leave a Comment

Leave a Reply